Ask the program to confirm assistance after the change
An existing manufacturer patient assistance program (PAP) approval is not enough to establish eligibility after an insurance change. Assistance may continue, require further review, or end under the specific program and product rules. The access team should report the change as instructed, obtain the program’s response, and record the outcome and enrollment end date. A new insurer’s coverage decision does not answer that PAP question.
The published evidence supports this program-specific approach. Gilead requests notification when an enrollee becomes insured and checks eligibility during enrollment. Lilly Cares requires patients to report income or insurance changes and states that the program decides eligibility. Neither source establishes a universal deadline for reporting, a guaranteed grace period, or the next shipment date after a change. Gilead patient information. Lilly Cares application, page 6.
For an access-team record, use the following outcome categories only when supported by the program’s communication. These are suggested documentation labels, not an industry classification or a promise that every program offers each outcome.
Continued: record what the program confirmed, the applicable end date, and any conditions. Retain the original approval alongside the post-change response.
Review pending: record the requested evidence, submission status, contact reference and follow-up owner. A pending review should remain distinguishable from an approval.
Changed or discontinued: record the effective date, stated reason and any next steps the program identifies. Verify the eligibility of any alternative support separately.
What the named programs actually publish
The comparison covers seven manufacturers, with separate NovoCare diabetes and growth-disorder rows. All linked materials were checked on October 16, 2026. A retrieval date is not a publication date: some pages carry explicit 2026 terms, Lilly’s form is dated December 2025, and several pages do not provide a current policy-year label. “Not stated” identifies a limit of the cited material, not proof that a program has no internal procedure. Federal Poverty Level is abbreviated FPL.
| Program and source | Insurance rule or scope | Change or renewal evidence | Published clock and limits |
|---|---|---|---|
| NovoCare diabetes PAP | Medicare or no insurance; private or commercial insurance excluded. Product restrictions also apply. | The page gives reapplication instructions, but no specific mid-enrollment insurance-change procedure. | Uninsured: 12 months. Medicare: current calendar year. Reapply 30 days before expiration; Part D applicants may apply after October 15 for the following year. Explicit 2026 eligibility section. |
| NovoCare growth-disorder support; PAP eligibility | Sogroya and Norditropin: income at or below 400% FPL. Government-benefit coverage or eligibility is excluded subject to listed exceptions. | HCP page ties free therapy to unchanged insurance or finances and specifies quarterly eligibility review. Detailed terms describe denial and appeal exceptions. | Up to one year; annual requalification, with the requalification process 30 days before expiration. No numbered change-reporting deadline published on these pages. |
| Lilly Cares application | Insurance eligibility varies by medication group. Group 4 includes a possible route when insurance does not cover the medication. Other exclusions apply. | Patient agrees to notify Lilly Cares of income or insurance changes; prescriber also agrees to report possible loss of eligibility. | Approval letter controls; generally 12 months or calendar-year end for Part D. Reapplication follows expiration. Form CMAT-02998 12/2025; no universal 30-day filing window stated. |
| Pfizer RxPathways updates | 2026: uninsured or government-insured, with income at or below 300% FPL and other criteria; commercial insurance excluded. | For Part D/Advantage applicants requesting a covered product, Medicare Prescription Payment Plan documentation is required. Renewal waiver requires prior submission and an unchanged plan. | No general enrollment duration stated in the 2026 section. Its continuation-to-end-date sentence is under 2025 changes and is conditional on continued eligibility. |
| Gilead Advancing Access PAP/MAP | Patient page offers free-medicine screening to uninsured patients and separate copay support for eligible commercially insured patients. | Call if insured while enrolled or free support is no longer needed; ongoing eligibility checks. Medicaid or AIDS Drug Assistance Program (ADAP) eligibility may prevent re-enrollment. | Up to 12 months; possible re-enrollment, subject to eligibility. No automatic post-change continuation period or fixed reporting deadline stated. |
| myAbbVie Assist income criteria | Limited or no insurance. Insured applicants’ financial need may be assessed using coverage, household income and medical expenses. | Excludes commercial arrangements requiring an application to myAbbVie Assist as a prerequisite to relevant product coverage. | Cited page does not state a mid-enrollment reporting deadline, enrollment duration or renewal-document schedule. Income and insurance criteria alone cannot establish those details. |
| Sanofi Patient Connection financial criteria | Uninsured or functionally uninsured; household income at or below 400% of current FPL. Page displays separate 2026 geographic tables. | This financial-eligibility page does not state how an existing enrollee reports a coverage change or what decision follows. | No enrollment or requalification clock stated here. Confirm product eligibility and change handling rather than importing another manufacturer’s rules. |
| GSK Part D eligibility | Requires a Medicare prescription drug plan, other program criteria, household income within the displayed geographic limits, and $600 paid for prescriptions in the current calendar year. | Privately insured readers are directed to separate access and copay programs. No mid-enrollment change procedure stated on this page. | Calendar-year spending test is published; enrollment expiration and renewal cycle are not. Footer is ©2024, so it should not be labeled a dated 2026 renewal policy. |
The useful distinction is between a published instruction and an unanswered operational question. A duty to notify does not specify when a shipment stops. A twelve-month term does not resolve eligibility after new coverage begins. A financial-eligibility page does not establish renewal documents. Where the matrix leaves a gap, ask the program that exact question and retain its answer rather than filling the gap with a standard workflow assumption.
Coverage type is a question for the specific product
Avoid treating possession of an insurance card as a uniform exclusion. AbbVie considers limited coverage and may assess insured applicants’ financial need. Sanofi uses the category functionally uninsured. These provisions make the scope of coverage relevant; neither page alone determines an enrolled individual’s post-change outcome. AbbVie insurance and income criteria. Sanofi financial criteria.
Medicaid handling also differs. The named sources describe exclusions, exceptions or conditional re-enrollment limits rather than one universal termination rule. A useful inquiry names the new coverage, its effective date and the prescribed product, then asks the program whether it changes current participation, renewal eligibility, or both. Do not replace that answer with an assumed industry policy.
Product scope matters even within one manufacturer. NovoCare’s 2026 diabetes section excludes Medicare beneficiaries with prescription drug coverage from Ozempic PAP access, while uninsured Ozempic applicants face a 200% FPL ceiling. That is a product-specific eligibility restriction, not evidence that every Medicare enrollee loses all manufacturer assistance. NovoCare product-specific terms.
A PAP review and a payer review can proceed as separate tasks. For the latter, see the article on prior authorization after an insurance change. Its payer-transition analysis does not establish eligibility for a manufacturer’s free-medicine program.
Keep the coverage, enrollment and review dates separate
For scheduling, distinguish the new insurance effective date, the PAP enrollment expiration, a periodic eligibility review and the next expected supply event. They can be different dates. Record each date from its own evidence instead of deriving all four from an annual approval. “Up to” twelve months also should not be rewritten as exactly 365 days.
NovoCare’s published Part D window allows next-year applications after October 15, 2026. In this review’s calendar, that means applications for 2027; it does not establish the final eligibility criteria for 2027. The source also has a separate 30-days-before-expiration instruction. Keep the stated window attached to the named program and enrollment type. NovoCare reapplication instructions.
Pfizer’s plan-change provision concerns its renewal documentation waiver. For covered products in the stated Part D/Advantage group, a changed plan fails the unchanged-plan condition. The page separately says missing payment-plan proof prevents processing above 138% FPL. This is not evidence that selecting a future plan instantly ends an existing PAP enrollment or that 2026 instructions automatically govern the next year. Pfizer’s 2026 requirements.
In the scheduling record, write the requested action and its basis in separate fields. “Prepare renewal evidence” can be an internal task; “submission accepted on this date” needs a program instruction or confirmation. That separation lets a team work ahead without presenting its chosen lead time as a manufacturer deadline. If the accepted filing date is unknown, leave it unresolved and assign someone to confirm it.
What OIG and CMS explain about assistance outside Part D
The 2005 HHS Office of Inspector General Special Advisory Bulletin describes reduced-risk arrangements for free drugs outside Part D. Its safeguards include plan notification, no Part D payment or TrOOP credit for subsidized drugs, assistance throughout the coverage year or remaining portion, availability for periodic use, contemporaneous drug records, consistent financial-need measures and compliance with then-existing CMS guidance. These are historical enforcement-guidance principles, not a safe harbor or an individual guarantee of continued enrollment. OIG bulletin, section III.C.
The bulletin also says programs need not disenroll every Medicare beneficiary merely because Part D exists, explaining that Part D enrollment is voluntary. It does not establish a right to remain eligible under any current manufacturer’s rules. Nor does it prove that continuation to term is the most common response to an insurance change. OIG bulletin, introductory qualifications.
CMS states that manufacturer PAPs can assist Part D enrollees outside the benefit and that this assistance does not count toward true-out-of-pocket costs, or TrOOP. CMS also requires a PAP attestation for programs wishing to exchange files to identify beneficiaries enrolled in Part D. This establishes benefit separation and an enrollment-information mechanism. CMS manufacturer PAP overview.
CMS’s coordination page describes two-way data exchanges with PAPs, state assistance programs and AIDS Drug Assistance Programs to coordinate prescription benefits and support accurate claims payment and TrOOP calculations. It does not describe a real-time alert for every coverage change, the program’s patient-level determination, or the timing of a shipment hold. A team should not treat participation in this exchange as evidence that a particular change has already been reported and resolved. CMS prescription-assistance data exchanges.
Build a record another team member can act on
The following is an editorial documentation framework for access and hub teams, not a claim that all programs require a particular file format or issue a new determination letter after every change. Its purpose is to keep the coverage event, evidence request and program response connected. Use the information the program supplies, identify what remains unanswered, and retain relevant documents through the team’s existing authorized records process.
| Record field | What to capture | What it helps resolve |
|---|---|---|
| Coverage event | Old and new coverage type, reported change date, effective date, and where the information came from. | Whether the inquiry concerns an active change or a prospective one. Keep an unknown effective date explicit. |
| Program and product | Exact assistance track and prescribed product, original approval reference, and the terms consulted. | Whether the answer applies to this PAP and medication rather than a separate copay or bridge program. |
| Notification | Date and method of contact, reference number if supplied, and which change was communicated. | Whether a contact note documents a completed notification or only an attempt to reach the program. |
| Requested evidence | The program’s actual request, applicable document period, submission date, and acknowledgement if received. | Whether evidence is still missing, under review, or accepted; submission alone should not be coded as approval. |
| Program response | Outcome, effective date, stated conditions and source of confirmation. Retain written notice where available; otherwise label the contact note accurately. | What the program has confirmed and what the team still needs to ask. Do not invent a determination letter. |
| Enrollment and supply | Confirmed enrollment end date, next review date if stated, and any separate supply instruction or shipment confirmation. | Whether participation, renewal review and medicine delivery have each been addressed. One date should not substitute for another. |
| Follow-up ownership | Named internal owner, next inquiry, target follow-up date and unresolved questions. | Who will close the remaining evidence gap and how another team member can continue the case. |
For example, imagine an enrollee reports a future insurance start date while the existing approval still lists a later expiration. The suggested record would retain both dates, log the notification, and ask whether the new coverage changes participation or requires additional evidence. Until the program responds, the team would record “review pending” rather than either guaranteed continuation or automatic discontinuation. This is an illustrative documentation exercise, not an observed case or a prediction of a manufacturer’s decision.
If a program requests proof of new coverage, record the request as received. If it asks for a denial, identify the relevant coverage or funding decision and whether the program specified an appeal requirement. Do not substitute a generic denial letter, assume all appeals must be exhausted, or collect a standard packet merely because a different manufacturer asks for it. The matrix shows why document requirements need to remain attached to their source.
Keep evidence status precise. A patient’s report can establish what the team was told; a submitted application can establish what was sent; an acknowledgement can establish receipt; a determination can establish the program’s decision. Labeling each item by what it actually shows makes the record useful without overstating its authority. When a response contains a condition, carry that condition into the task list rather than summarizing it away as “approved.”
For a verbal response, a useful contact note records the date, contact channel, reference supplied and the actual question answered. Ask for written confirmation when available, but do not imply that every program publishes or promises a special post-change notice. If the answer addresses continued enrollment but leaves shipment timing open, track the supply question separately. This framework documents uncertainty instead of converting it into an unsupported assurance.
Recheck the rule without assuming the result
Use the original enrollment end date, a reported coverage event, a program evidence request and a published terms update as review prompts. Income tables, product availability and program conditions can change. Where a page has no dated policy version, save the retrieval date with the material consulted; do not describe an undated page as a formally issued annual policy. The date records what the team checked, while the program’s response records what it decided.
The public sources establish meaningful differences in notification duties, insurance conditions and review clocks. They do not measure how often assistance continues, how often programs learn of changes at renewal, or how frequently shipments are interrupted. Those outcomes should remain unknown here. The practical endpoint is a traceable program response with its conditions and dates, plus a clearly assigned next step when the response is incomplete.
Sources
Primary materials checked October 16, 2026. Manufacturer links support their own stated terms; the OIG bulletin is dated November 22, 2005, and the CMS pages describe the Part D coordination framework.
NovoCare HCP: growth-disorder assistance and quarterly review
Lilly Cares application, CMAT-02998 12/2025; pages 1, 6 and 8
Pfizer RxPathways: distinguish the 2026 requirements from the 2025 changes
Gilead Advancing Access: PAP/MAP change reporting and enrollment
HHS OIG: 2005 Special Advisory Bulletin, especially section III.C
CMS: prescription-assistance coordination and Part D data exchange
